Navigation Links
Could a tumor suppressor also fight obesity?
Date:8/25/2011

PHILADELPHIAThe hormone receptor guanylyl cyclase C (GCC) has been established as a suppressor of colorectal cancer tumors, but new evidence from Thomas Jefferson University suggests it may also help fight one of the country's biggest pandemics: obesity.

Reporting in the August 25 online issue of the Journal of Clinical Investigation, Scott Waldman, M.D., Ph.D., chairman of the Department of Pharmacology and Experimental Therapeutics at Jefferson, and colleagues found that silencing GCC affected appetite in mice, disrupting satiation and inducing obesity. Conversely, mice who expressed the hormone receptor knew when to call it quits at mealtime.

Revealing a never-before-shown endocrine axis between the intestine and hypothalamus, the research could provide novel therapeutic targets to control appetite, obesity and the metabolic syndrome, a promising notion, given that one-third of the U.S. population is considered obese.

Until now, the role of GCC outside the gut has remained elusive. Dr. Waldman and his team have previously shown its role as a tumor suppressor and biomarker that reveals occult metastases in lymph nodes. But its role in appetite is new and surprising territory.

"We were working with GCC-deficient mice to look at its role in tumorigenesis in the intestine," said Dr. Waldman. "Then the mice grew up, and we noticed something: They got fatter.

"We couldn't understand why it was happening, because GCC is expressed predominantly in intestine, and there was no indication that it regulated any function that had to do with metabolism and nutrient uptake."

To investigate this, Dr. Waldman, who also leads the Gastrointestinal Malignancies Program at the Kimmel Cancer Center at Jefferson, and his colleagues raised both GCC mice and GCC deficient mice, tracking their weight, satiation responses, hepatic and serum triglyceride measurements, hormone receptor expression, and physical activity.

When food was digested by the mice, they found, the gut released hormones into the blood stream, not just within the intestines, and up into the brain, where the hormone receptors were triggered. Mice with GCC knew when to stop, but hormone receptor-deficient mice never got the message that their stomachs were full. They simply kept eating and became obese.

"They got to be diabetic and developed the metabolic syndrome, fatty livers, etc." Dr. Waldman said. "We ruled out usual suspects: gastroenterology function was normal. They weren't more sedentary than wild type mice. And they did not have abnormal metabolism. We realized they just have a different appetite."

The research offers up a new neural-gut axis that explains appetite more, but it still begs some questions: Do obese people possess little to no GCC? And if so, does that mean obese people have a genetic disposition to gain weight?

It's possible, said Dr. Waldman, but it's still unclear. There is the possibility that obese people do not have the receptor or they do not release enough hormones to trigger the receptor. More studies are needed to better explain this, he added.

"Obesity could be biological, and not behavioral," said Dr. Waldman. "But there is no evidence here that confirms that; however, knowing this new information opens that possibility."


'/>"/>

Contact: Steve Graff
stephen.graff@jefferson.edu
215-955-6300
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Premature Death Could Await Obese Kids
2. Six Other E. colis Could Be Lurking In Your Valentine Days Dinner
3. Tiny fruit fly could offer big clues in fight against obesity, researcher says
4. New Book Reveals How Qigong Could Be The Eastern Answer To Botox
5. Chocolate lovers could be lowering their risk of stroke: Study
6. Charging less for more effective treatments could reduce health care costs while improving health
7. Clinical trial underway: Miniature ultrasound device could revolutionize pain relief
8. UAB-led study shows simple steps could reduce stillbirths by up to 1 million
9. Most maternal deaths in sub-Saharan Africa could be avoided
10. Dolphins could be ideal model to study human cervical cancer, UF veterinarians say
11. New Technology Could Widen Reach of Vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ProVest ... the greater Dallas, Miami, and Raleigh regions, is organizing an extended charity drive ... rare and deadly chromosome abnormality. , After struggling since birth with several health ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... process to promote standards of excellence for the field of eating disorders, announces ... 22 – 25, 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... ... , ... Talented host, actor Rob Lowe, is introducing a ... episode of "Success Files," which is an award-winning educational program broadcasted on PBS ... in-depth with passion and integrity. , Sciatica occurs when the sciatic nerve in ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
(Date:9/28/2017)... -- Cohen Veterans Bioscience and Early Signal Foundation announce ... home sensors for real-time monitoring of patients with trauma-related ... organization focused on disruptive health solutions for rare disorders ... to record and integrate behavioral, cognitive, physiological and contextual ... ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
Breaking Medicine Technology: